Philine van den Tol is a senior executive and entrepreneur with over 20 years of experience in the life science industry. Van den Tol is president, clinical trial operations of CATO SMS. In her position, she is responsible for global clinical trial operations, including executive oversight, strategic planning and leadership, and day-to-day operations within new and ongoing clinical projects. In addition, van den Tol is managing director of CATO SMS’ Amsterdam office.
Preceding her current role, van den Tol served as chief executive officer of SMS-oncology, where she built and led one of the world’s leading boutique clinical research organizations solely dedicated to oncology. With her strong entrepreneurial sense and determination for excellence and client satisfaction, van den Tol was an essential lead in the rapid expansion of SMS-oncology, which resulted in the successful merger in the fall of 2019. Van den Tol built and led the company, focusing on growth, reputation, sales, and development of improved business processes and systems. Van den Tol previously served as chief operating officer, driving strong growth and high performance in the company’s largest business segment. Prior to SMS-oncology, van den Tol guided international breast cancer research at the Dutch Breast Cancer Research Group (BOOG) as clinical study manager. Van den Tol began her career in clinical research and oncology as central data manager at the Dutch Comprehensive Cancer Center West (CCC).
Van den Tol studied innovative business management at the University of Applied Sciences in Leiden, Netherlands. She also completed her training in safety, health and environment management education and served as staff physiotherapist at the Leiden University Medical Center.